Full Product Name
FXN siRNA (Mouse)
Product Synonym Names
FRDA; Frataxin mitochondrial; Fxn
Product Gene Name
FXN sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O35943
Specificity
FXN siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse FXN gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of FXN sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
FXN sirna
siRNA to inhibit FXN expression using RNA interference
Applications Tested/Suitable for FXN sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for FXN. It may not necessarily be applicable to this product.
NCBI Accession #
NP_032070.1
[Other Products]
NCBI GenBank Nucleotide #
NM_008044.2
[Other Products]
UniProt Primary Accession #
O35943
[Other Products]
UniProt Related Accession #
O35943[Other Products]
Molecular Weight
22,924 Da
NCBI Official Full Name
frataxin, mitochondrial
NCBI Official Synonym Full Names
frataxin
NCBI Official Symbol
Fxn??[Similar Products]
NCBI Official Synonym Symbols
FA; X25; FARR; Frda
??[Similar Products]
NCBI Protein Information
frataxin, mitochondrial
UniProt Protein Name
Frataxin, mitochondrial
UniProt Gene Name
Fxn??[Similar Products]
UniProt Synonym Gene Names
Frda; Fxn??[Similar Products]
UniProt Entry Name
FRDA_MOUSE
UniProt Comments for FXN
FXN: Promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe(2+) to proteins involved in these pathways. May play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the monomeric form has in vitro ferroxidase activity. May be able to store large amounts of iron in the form of a ferrihydrite mineral by oligomerization; however, the physiological relevance is unsure as reports are conflicting and the function has only been shown using heterologous overexpression systems. Modulates the RNA-binding activity of ACO1. Defects in FXN are the cause of Friedreich ataxia (FRDA). FRDA is an autosomal recessive, progressive degenerative disease characterized by neurodegeneration and cardiomyopathy it is the most common inherited ataxia. The disorder is usually manifest before adolescence and is generally characterized by incoordination of limb movements, dysarthria, nystagmus, diminished or absent tendon reflexes, Babinski sign, impairment of position and vibratory senses, scoliosis, pes cavus, and hammer toe. In most patients, FRDA is due to GAA triplet repeat expansions in the first intron of the frataxin gene. But in some cases the disease is due to mutations in the coding region. Belongs to the frataxin family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Mitochondrial; EC 1.16.3.1; Motility/polarity/chemotaxis
Cellular Component: mitochondrion; cell; cytoplasm; cytosol
Molecular Function: ferroxidase activity; 2 iron, 2 sulfur cluster binding; enzyme binding; ferric iron binding; metal ion binding; ferrous iron binding; iron-sulfur cluster binding; oxidoreductase activity
Biological Process: cellular iron ion homeostasis; positive regulation of axon extension; proprioception; ***** walking behavior; embryonic development ending in birth or egg hatching; protein autoprocessing; iron incorporation into metallo-sulfur cluster; positive regulation of lyase activity; transport; positive regulation of cell proliferation; response to iron ion; positive regulation of oxidoreductase activity; oxidative phosphorylation; mitochondrion organization and biogenesis; negative regulation of multicellular organism growth; iron-sulfur cluster assembly; positive regulation of metalloenzyme activity; positive regulation of transferase activity; negative regulation of organ growth; positive regulation of cell growth; iron ion homeostasis; aerobic respiration; ion transport; negative regulation of apoptosis; heme biosynthetic process
Research Articles on FXN
1. Reduced expression of frataxin in Friedreich's ataxia leads to elevation of COX2-mediated oxylipin synthesis stimulated by increases in transcription factors that respond to increased reactive oxygen species.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
